Updated results were disclosed Wednesday night from a mid-stage clinical trial of Incyte’s epacadostat combined with Merck’s Keytruda to treat patients with metastatic melanoma.

The new data, culled from the study Incyte (INCY) calls ECHO-202, look good, matching or exceeding investor expectations. Here’s a rundown:

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • As a Melanoma patient who has gone through 38 rounds of IL2 in 2010 and wondering when the Melanoma would become active again in my body, well I don’t have that on my mind anymore, I found out Thursday August 31 that it’s back, I was seeking some information, doing a little research for my options.
    I find it disgusting that you would withhold such vital information from the public and demand a ransom for it, I will be sure to tell everyone I know to avoid your website and cancel their subscriptions if they have one.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy